Context-Specific Hormonal Syndromes in ACC

Hormonal Evaluation

Context-specific hormonal syndromes in adrenocortical carcinoma (ACC) are atypical endocrine presentations that fall outside the more familiar patterns of overt cortisol, androgen, or mineralocorticoid excess. Within hormonal evaluation, they reflect a broader feature of ACC biology: malignant adrenocortical tissue may produce steroids inefficiently, along multiple pathways at once, or predominantly as precursors and metabolites rather than the end products emphasized in routine testing.¹²³

These presentations complicate the conventional distinction between “functioning” and “nonfunctioning” adrenal tumors. In ACC, endocrine activity may be clinically subtle despite a large or aggressive lesion, and apparently nonfunctioning tumors on standard assays may still show disordered steroidogenesis on more specialized analysis.¹³ The resulting phenotype may therefore be discordant with tumor size, imaging suspicion, or classic adrenal syndromic labels.

The evidence base is limited and uneven. Most published data consist of case reports, tumor-specific biochemical observations, and indirect comparative material rather than prospective human studies, so prevalence, specificity, and prognostic value remain uncertain.¹²³ Accordingly, atypical hormonal findings may raise suspicion, explain unusual presentations, or help interpret discordant results, but they do not establish malignancy on their own and do not replace standard endocrine, imaging, surgical, or pathologic assessment.

Diagnostic context

Hormonal evaluation in ACC is performed alongside assessment of tumor morphology, stage, and resectability. In that setting, context-specific hormonal syndromes are best understood as consequences of disrupted adrenal cortical differentiation, with loss of normal zonal organization and uneven steroidogenic enzyme expression leading to mixed, incomplete, or inefficient hormone production.¹³

A consistent inference across the available literature is that routine hormone categories may underrepresent the biologic complexity of ACC.¹³ What is less reliable is any attempt to infer malignancy, tumor subtype, or clinical course from atypical biochemistry alone, because supporting data are largely retrospective and case-based.¹² In practice, hormonal abnormalities are most informative when interpreted together with imaging, histopathology, and the broader clinical picture.

This framework helps organize the main endocrine patterns described in the literature.

Major phenotypes

Mixed cortical secretion

Some ACCs show secretion across more than one adrenal axis, such as concurrent mild aldosterone excess and subclinical cortisol autonomy rather than a single dominant syndrome.¹ This pattern is biologically consistent with disorganized intratumoral enzyme expression and may explain why hormonal findings can appear disproportionately mild relative to tumor burden.

The most dependable conclusion is that small abnormalities in more than one steroid pathway may still be clinically meaningful in a suspicious adrenal mass.¹ However, the frequency and specificity of mixed secretion remain unclear, and current evidence does not show that it reliably distinguishes ACC from other adrenal neoplasms. Clinically, borderline multi-axis abnormalities may warrant integration rather than dismissal when other features raise concern for ACC.

Apparent nonfunctioning tumors with altered steroidogenesis

Some tumors classified as nonfunctioning by standard plasma testing nonetheless show evidence of abnormal steroid synthesis within the tumor itself.³ This suggests that “nonfunctioning” in ACC may at times reflect limitations of routine detection rather than true endocrine silence.

The reliable point is that normal screening studies for cortisol, aldosterone, renin, or catecholamine-related pathways do not exclude disordered steroidogenesis in ACC.³ What remains uncertain is when additional specialized testing changes management or outcomes. The practical implication is that a normal hormonal screen should not outweigh strong radiographic, operative, or pathologic concern for malignancy.

Unusual precursor and metabolite production

Rare reports describe ACC associated with atypical urinary steroid precursor or metabolite patterns not routinely captured in standard adrenal workups.² These findings are compatible with incomplete enzymatic conversion or pathway diversion within malignant adrenal tissue and support a broader view of ACC as a disorder of dysregulated steroidogenesis rather than only excess secretion of canonical end hormones.

Here, the biologic plausibility is stronger than the clinical validation.² Evidence comes mainly from isolated cases, so unusual metabolite patterns may provide mechanistic insight or explain unusual endocrine manifestations in selected patients, but they are not established routine markers of ACC.

Evidence synthesis and clinical interpretation

Across the included literature, the recurring theme is mismatch between clinical syndrome, measured hormone output, and underlying tumor biology. ACC may present with mild, mixed, or apparently absent endocrine abnormalities despite substantial disease, and the measured phenotype may not fit neatly into standard adrenal categories.¹³ This pattern supports the concept that intratumoral heterogeneity in steroidogenic pathways may be as important as tumor size in determining presentation.

That interpretation is coherent across reports but remains supported mainly by mechanistic reasoning and small observational evidence rather than prospective validation.¹³ The clinical implication is cautious flexibility: standard hormonal testing remains necessary, but discordant or unexpectedly limited abnormalities do not exclude hormonally active ACC.

This same principle informs the possible role of expanded steroid analysis. Urinary metabolite profiling or tissue steroid analysis may help explain atypical presentations when conventional assays are unrevealing.²³ However, available evidence does not support replacing standard hormonal evaluation with specialized metabolite testing, and interpretation remains dependent on local expertise.

Differential diagnosis and interpretive pitfalls

Because atypical hormonal syndromes are nonspecific, the main pitfall is false reassurance from normal or only mildly abnormal routine endocrine studies. In ACC, such findings may reflect incomplete steroid synthesis or mixed pathway activity rather than true hormonal inactivity.³ The converse pitfall is overinterpreting unusual steroid findings without adequate consideration of more common benign or non-ACC explanations for adrenal hormone abnormalities.

This is particularly relevant when presentations overlap with bilateral adrenal disorders or pituitary-driven hypercortisolism. Bilateral nodular adrenal disease may mimic malignant endocrine phenotypes, and pituitary pathology may complicate interpretation of adrenal hormonal abnormalities, so laterality, imaging pattern, and clinicopathologic correlation remain central to differential diagnosis.⁴⁵ Compared with these established differential considerations, most proposed atypical hormonal signatures of ACC remain weakly validated.

Dynamic cortisol-based tests add further uncertainty. Indirect veterinary reports suggest that adrenocortical carcinomas may show normal, low, or equivocal responses on stimulation or suppression testing, and that precursor responses may at times reveal abnormalities not captured by cortisol alone.⁶⁷⁸ These data are not directly generalizable to human ACC, but they support a cautious practical point: standard dynamic tests may incompletely characterize disordered steroidogenesis in adrenal neoplasia.

Role in management and research

In current ACC care, context-specific hormonal syndromes mainly refine interpretation rather than define a separate management pathway. They support integrating endocrine findings with imaging, surgical planning, and pathology, and they argue against allowing biochemical ambiguity to override strong morphologic suspicion for ACC.¹³ Relative to surgery, staging, and histologic confirmation, their role remains complementary rather than determinative.

For research, these syndromes highlight the need for more systematic characterization of steroidogenic heterogeneity in ACC. Steroid metabolomics and enzyme-expression studies may eventually clarify biologic subtypes or improve discrimination between malignant and benign adrenal tumors, but current evidence is too sparse to support standardized algorithms or strong prognostic claims.¹²³

Included Articles

• PMID 5769579: A pediatric ACC case showed marked preoperative urinary excretion of 16-OH-pregnenolone and pregn-5-en-3 beta,16 alpha,20 alpha-triol, with 16-OH-pregnenolone reported for the first time in ACC urine and excreted predominantly as a glucuronidated conjugate. The authors suggest this unusual steroid pattern may relate to the patient’s endocrine manifestations, especially hypoglycemia.²

• PMID 9559845: This case report describes a nonfunctioning ACC with normal plasma cortisol, aldosterone, renin, and catecholamine studies despite imaging suspicious for malignancy. Tumor steroid analysis showed markedly reduced mitochondrial P450c11B activity with low intratumoral cortisol and corticosterone, illustrating biochemical nonhyperfunction despite altered steroidogenesis.³

• PMID 27430645: This case report describes ACC with mild primary aldosteronism and subclinical Cushing syndrome despite a large tumor, linking the phenotype to disorganized intratumoral steroidogenic enzyme expression. The findings support that ACC hormone output may be inefficient and clinically subtle because steroidogenic pathways are poorly coordinated across tumor cells.¹

• PMID 28739615: A 2017 case report on primary bilateral adrenal nodular disease with Cushing syndrome is indirectly relevant to ACC because it illustrates a differential diagnosis in which adrenal cortisol excess and nodularity may resemble malignant endocrine presentations without representing ACC itself.⁴

• PMID 10371012: A small veterinary series of dogs with functional adrenocortical tumors, including carcinomas, found that ACTH stimulation and low-dose dexamethasone suppression testing often gave unexpectedly normal, low, or equivocal cortisol results. The report also noted that ACTH-stimulated 17-hydroxyprogesterone could be abnormal even when cortisol responses were not, indirectly supporting the concept that atypical steroidogenesis can complicate interpretation of standard dynamic testing.⁶

• PMID 1413443: A 1992 veterinary case series described four cats with hyperadrenocorticism, including one with pathologically confirmed adrenocortical carcinoma and nonsuppression on low-dose dexamethasone testing. Its relevance to human ACC is indirect, but it broadly supports the note’s caution that dynamic cortisol tests can be abnormal in adrenal carcinoma without establishing a uniform testing pattern.⁷

• PMID 29665752: A canine pituitary histopathology series found that adenohypophyseal proliferations were associated with hyperadrenocorticism and showed a positive trend with adrenocortical hyperplasia. For this note, the article provides indirect differential-diagnostic support that pituitary-driven disease can mimic adrenal endocrine presentations and complicate interpretation of bilateral or adrenal cortical abnormalities, but it does not directly study ACC.⁵

• PMID 9652047: A veterinary case report of adrenal cortical carcinoma in a parrot described hyperadrenocorticism documented by elevated corticosterone, illustrating that functioning adrenal carcinoma may be demonstrable through species-specific steroid measurements rather than standard cortisol-based testing. This is indirect evidence only, but it is consistent with the note’s emphasis on cautious interpretation of atypical endocrine assays in adrenal neoplasia.⁸

References

Footnotes

1. Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.. Endocr Pathol. 2017. PMID: 27430645. Local full text: 27430645.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³

2. Isolation and identification of 16-OH pregnenolone (pregn-5-en-3 beta,16 alpha-diol-20-one) in urine from a patient with adrenocortical carcinoma.. Steroids. 1969. PMID: 5769579. Local full text: 5769579.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

3. Nonfunctioning adrenal cortical cancer and analysis of the steroidogenic activity of the tumor: a case report.. Int J Urol. 1998. PMID: 9559845. Local full text: 9559845.md ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴

4. Primary bilateral adrenal nodular disease with Cushing’s syndrome: varying aetiology.. BMJ Case Rep. 2017. PMID: 28739615. Local full text: 28739615.md ↩ ↩²

5. Histopathologic Findings in Canine Pituitary Glands.. Vet Pathol. 2018. PMID: 29665752. Local full text: 29665752.md ↩ ↩²

6. Dynamic adrenal function testing in eight dogs with hyperadrenocorticism associated with adrenocortical neoplasia.. Vet Rec. 1999. PMID: 10371012. Local full text: 10371012.md ↩ ↩²

7. Hyperadrenocorticism in four cats.. Vet Q. 1992. PMID: 1413443. Local full text: 1413443.md ↩ ↩²

8. Hyperadrenocorticism caused by an adrenal carcinoma in a parrot.. Vet Q. 1998. PMID: 9652047. Local full text: 9652047.md ↩ ↩²